# README Best Practices for Healthcare Technology Projects: Compliance, Security, Visuals, Metrics, and Professional Standards

## Executive Summary: Why Healthcare READMEs Must Be Different

A healthcare technology README.md is not a marketing page or a generic developer onboarding file. It is a trust artifact and a compliance anchor that signals clinical responsibility, regulatory awareness, and security competence. In regulated contexts, the README must be precise and restrained, documenting facts and evidence that matter to clinicians, compliance officers, security reviewers, regulators, and technical integrators. It must clarify intended use, data boundaries, security controls aligned to the Health Insurance Portability and Accountability Act (HIPAA), and it must do so without exposing Protected Health Information (PHI) or compromising intellectual property. For Software as a Medical Device (SaMD), it must provide traceability and verification/validation (V&V) summaries while pointing reviewers to canonical evidence in the quality management system (QMS) rather than duplicating it.

Healthcare software operates under heightened scrutiny. The HIPAA Security Rule defines technical safeguards, policy expectations, and evidence types that are relevant whenever electronic PHI (ePHI) is created, received, maintained, or transmitted. These safeguards emphasize access control, audit controls, integrity, person/entity authentication, and transmission security, all of which should be represented in documentation without revealing sensitive implementation details that could invite attack or violate confidentiality norms.[^1] In parallel, the U.S. Food and Drug Administration (FDA) has clarified documentation expectations for device software functions, including system and software architecture design, risk management, and testing summaries, with deeper documentation expected at higher “Documentation Levels.”[^2] Good documentation practices (GDocPs) further require version control, approvals, change management, and archival discipline.[^3]

This report translates those regulatory and quality principles into practical guidance for engineering teams. It recommends a minimal, essential structure for the healthcare README; describes how to present compliance and security information; lays out visual diagram best practices for architecture and data flows; defines performance metrics to include; and prescribes professional presentation standards for regulated environments. It concludes with an implementation checklist and an appendix mapping README components to regulatory sources.

Information gaps exist. There is no single regulation that defines a universal README schema. This report therefore anchors to the HIPAA Security Rule, FDA guidance for device software functions, and established good documentation practices to propose a pragmatic structure. Similarly, quantitative thresholds for performance metrics often depend on device class, intended use, and clinical context; readers should align numeric targets with their risk management files and premarket submissions rather than expecting prescriptive values here.

---

## Scope, Audience, and Methodology

This report focuses on U.S. contexts (HIPAA and FDA) and SaMD scenarios, with secondary applicability to non-device health software that handles ePHI. The primary audiences are engineering leads, product managers, technical writers, regulatory and compliance specialists, security engineers, and quality leaders responsible for public-facing documentation. The methodology synthesizes requirements and expectations from the HIPAA Security Rule (including official technical safeguards), FDA guidance on premarket submissions for device software functions, the R Foundation’s guidance on regulated use of statistical software, and good documentation practices in medical device environments.[^4][^5][^6][^3]

We adopt four editorial principles:

- Evidence-based: statements are grounded in regulatory guidance and authoritative publications.
- Audit-ready: the README and linked evidence artifacts support audit and inspection.
- Privacy-first: no PHI in public docs; sensitive details belong behind access controls.
- Traceability: cross-reference QMS documents and premarket artifacts rather than duplicating content.

Because HIPAA emphasizes flexibility of approach and FDA expectations scale with documentation level, the guidance here is practical rather than prescriptive, and it highlights how to present facts succinctly while maintaining compliance integrity.[^1][^2]

---

## Regulatory Landscape: HIPAA, FDA SaMD, and Good Documentation Practices

Healthcare projects intersect with multiple regulatory and quality frameworks. The HIPAA Security Rule sets the baseline for administrative, physical, and technical safeguards when handling ePHI. For medical devices and SaMD, FDA guidance defines what to include in premarket submissions, with “Documentation Levels” that determine depth (Basic vs Enhanced). In GxP-regulated environments, good documentation practices—part of broader quality system expectations—govern how records are created, reviewed, approved, retained, and retrieved.

### HIPAA Security Rule Essentials

The HIPAA Security Rule establishes security standards for protecting ePHI. Its administrative, physical, and technical safeguards define “what good looks like” in terms of policies, procedures, and controls. Technical safeguards include access control (unique user identification, emergency access procedures, automatic logoff, encryption/decryption), audit controls, integrity, person/entity authentication, and transmission security.[^1][^4] Retention expectations are also explicit: many required records must be maintained for at least six years, and access to privacy rights records must be provided in a timely manner (e.g., within 30 days), which has implications for documentation and change control discipline.[^7]

To illustrate how technical safeguards map to documentation choices, the following table synthesizes the standards and presents appropriate README-level representations. These representations signal compliance without exposing sensitive system design details.

Table 1: HIPAA Technical Safeguards mapped to README representation

| HIPAA Technical Safeguard Standard | Implementation Specification | What to Record in README | Evidence to Link (Internal) | Notes |
|---|---|---|---|---|
| Access Control | Unique User Identification (Required) | Statement that unique user IDs are enforced; no credential specifics | Access control policy; IAM configuration summary | Avoid publishing authentication mechanisms or formats |
| Access Control | Emergency Access Procedure (Required) | High-level description of emergency access; governance only | Emergency access SOP; test evidence | No PHI or step-by-step runbooks in public docs |
| Access Control | Automatic Logoff (Addressable) | Confirmation that automatic session termination is configured | Configuration standard; session management policy | Avoid timers or exact thresholds |
| Access Control | Encryption/Decryption (Addressable) | Confirmation that encryption is implemented for ePHI at rest/in transit | Crypto policy; KMS/HSM overview | Do not expose algorithms or keys |
| Audit Controls | — | Confirmation that audit logging is in place and reviewed per policy | Audit control plan; review logs; monitoring SOP | Cite review cadence and scope, not raw logs |
| Integrity | Mechanism to Authenticate ePHI (Addressable) | Confirmation that checksums/digital signatures protect against improper alteration | Integrity control SOP; validation evidence | No PHI in examples |
| Person/Entity Authentication | — | Confirmation of identity verification before access | Authentication policy; MFA/SSO overview | Avoid enumerating specific factors publicly |
| Transmission Security | — | Confirmation that ePHI transmission is protected end-to-end | TLS policy; secure transport SOP | Do not disclose cipher suites or endpoints |

![HIPAA Technical Safeguards overview (HHS Security Series)](.pdf_temp/viewrange_chunk_2_6_10_1762307725/images/xmd7qc.jpg)

The image above, drawn from the HHS security series, summarizes the five technical safeguard standards and highlights the flexibility of implementation. In a README, teams should signal that these safeguards exist and are governed via internal policies and SOPs, with no PHI or sensitive details exposed. This approach respects the HIPAA principle of technology neutrality while demonstrating due diligence.[^1]

### FDA SaMD and Software Documentation Expectations

For SaMD, the FDA describes premarket submission content and documentation depth based on a software function’s risk and complexity. Required elements typically include software description, intended use, system and software architecture design, risk management documentation, and testing summaries, with deeper design and verification artifacts expected in Enhanced Documentation Levels.[^2][^5] More recent FDA communications emphasize updated expectations and help sponsors determine whether Basic or Enhanced documentation applies.[^8][^10]

Table 2 below summarizes a subset of documentation elements, contrasting the legacy 2005 guidance with the 2023 guidance. This comparison shows how expectations have evolved, especially around architecture, risk management, and testing depth.

Table 2: FDA software documentation elements—legacy (2005) vs current (2023) guidance

| Documentation Element | 2005 Guidance | 2023 Guidance | Key Difference / Emphasis |
|---|---|---|---|
| Level of Concern / Documentation Level | Defined Level of Concern | Documentation Level evaluation (Basic vs Enhanced) with rationale | Shift in framing; deeper documentation at Enhanced level |
| Software Description | Required | Required | Similar core, but more explicit linkage to risk and architecture |
| Hazard Analysis vs Risk Management File | Device Hazard Analysis | Risk Management File (plan, assessments, controls, report) | Alignment with modern risk management practices |
| Architecture | Architecture Design Chart | System and Software Architecture Design | Stronger emphasis on modularity, interfaces, data flows |
| Detailed Design | SDS required in certain cases | SDS expected at Enhanced level | Depth scales with documentation level |
| Traceability | Standalone traceability analysis | Embedded traceability in design and testing artifacts | Traceability consolidated within documents |
| Verification & Validation | V&V documentation | Software testing across levels; system tests emphasized at Enhanced | Testing scope broadened for Enhanced |
| Version History | Revision Level History | Software Version History | Explicit version testing rationale |
| Unresolved Anomalies | Unresolved Anomalies | Unresolved Software Anomalies | Risk assessment for each anomaly highlighted |

Table 3 clarifies typical artifacts expected at Basic vs Enhanced Documentation Levels.

Table 3: Documentation Levels (Basic vs Enhanced)—typical artifacts and expectations

| Documentation Level | Typical Artifacts | Expectation |
|---|---|---|
| Basic | Software description; intended use; high-level architecture; risk file; system-level testing summary; version history; unresolved anomalies | Core design and testing evidence sufficient to support safety and effectiveness |
| Enhanced | All Basic artifacts plus detailed design (SDS); expanded verification (unit/integration protocols and reports); development environment description; configuration and maintenance practices | Deeper design and verification to mitigate higher risk/complexity |

The table indicates how depth scales with risk. In READMEs, teams should reference the presence of these artifacts and link to internal QMS locations rather than duplicating content. This supports auditability and avoids sprawling public documentation.[^2][^5][^8]

### Good Documentation Practices (GDocPs)

GDocPs define how regulated documentation is created, reviewed, approved, issued, recorded, stored, and archived. Practices include version control, approvals, change management, and audit trails—principles equally applicable to public READMEs and internal evidence. In healthcare contexts, consistency, traceability, and readability are essential to pass audits and sustain efficiency across releases.[^3]

---

## Essential Sections of a Healthcare Technology README

A healthcare README should be succinct yet complete, with each section fulfilling a specific purpose for clinical, compliance, security, and integration stakeholders.

- Project Overview and Intended Use: Define the clinical or operational purpose and intended users. If SaMD, explicitly state the medical intended use and claims, linking to the risk management file and labeling.
- Compliance and Security Summary: Summarize HIPAA applicability, Business Associate Agreements (BAAs), safeguard mappings, audit controls, and retention. Use a compliance matrix for clarity.
- Architecture and Data Flows: Provide an overview diagram and narrative without sensitive specifics. Reference detailed architecture documentation.
- API and Interface Documentation: Summarize public interfaces and link to detailed specifications. Include integration constraints and error handling validation references.
- Installation, Configuration, and Deployment: Provide high-level steps and link to environment hardening guides. Avoid secrets and environment-specific details.
- Testing, Validation, and Traceability: Summarize V&V efforts, link to test plans and reports, and include traceability references.
- Performance and Clinical Metrics: Present clinical, analytical, reliability, and security metrics with clear definitions and evidence pointers.
- Release, Versioning, and SBOM: Include version history, unresolved anomalies, and SBOM pointers.
- Support, Incident Response, and Vulnerability Disclosure: Provide contacts, safety communications, and a vulnerability handling process.
- Licensing and Legal Notices: Include licensing, third-party components, and attributions.
- How to Contribute (Optional): Governance expectations for contributions to regulated projects.

Table 4 maps these sections to their regulatory anchors and evidence references.

Table 4: README section-to-requirement mapping

| README Section | Primary Regulatory Anchor | Key Evidence to Reference |
|---|---|---|
| Overview & Intended Use | FDA device software functions guidance | Intended use statement; risk management file; labeling |
| Compliance & Security Summary | HIPAA Security Rule | Safeguard mapping; BAA status; audit control policy |
| Architecture & Data Flows | FDA expectations; IEC 62304 concepts | High-level architecture diagram; interface catalog |
| API & Interface Documentation | FDA interoperability expectations | API specs; integration validation evidence |
| Installation/Configuration | HIPAA technical safeguards; GDocPs | Environment hardening SOP; configuration standards |
| Testing, Validation, Traceability | FDA software V&V; statistical software guidance | Test plans/reports; traceability matrices |
| Performance & Clinical Metrics | FDA validation pillars; R/FDA guidance | Clinical/analytical performance evidence |
| Release, Versioning, SBOM | FDA version history; IEC 62304 release records | Release notes; SBOM; unresolved anomalies |
| Support & Incident Response | HIPAA contingency planning | Incident response SOP; breach notification procedure |
| Licensing & Legal Notices | GDocPs | Software license; third-party attributions |
| How to Contribute (Optional) | GDocPs | Contribution governance policy |

### Overview and Intended Use

State the clinical purpose and intended users clearly. For SaMD, specify intended use and medical claims, and reference the risk management file and labeling materials that support those claims. This section anchors the reader’s understanding of scope and safety considerations.[^2]

### Compliance and Security Summary

Define HIPAA applicability. If the software interacts with covered entities or processes ePHI, state whether BAAs are in place. Summarize safeguard mappings and mention audit controls and retention. A concise matrix can make the overview scan-able without burying details.

Table 5: HIPAA safeguards mapped to README statements and evidence links

| Safeguard Area | README Statement | Evidence Pointer |
|---|---|---|
| Access Control | Unique IDs; emergency access; auto logoff; encryption at rest/in transit | IAM policy; emergency access SOP; session management; crypto policy |
| Audit Controls | Activity logging and review cadence | Audit control plan; review logs; monitoring SOP |
| Integrity | Mechanisms to authenticate ePHI (e.g., checksums/digital signatures) | Integrity SOP; validation evidence |
| Authentication | Identity verification prior to access | Authentication policy; MFA/SSO overview |
| Transmission Security | Secure transport for ePHI | TLS policy; secure transport SOP |

![HIPAA Security Rule technical safeguards context](.pdf_temp/viewrange_chunk_2_6_10_1762307726/images/sj8bfi.jpg)

The image highlights the technical safeguards landscape. In the README, present only high-level confirmations and link to internal evidence to avoid exposing sensitive operational specifics.[^1][^7]

### Architecture and Data Flows

Provide a high-level system and software architecture diagram. Label runtime environments, hosting/network isolation, and external integrations without revealing PHI or sensitive endpoints. The diagram should emphasize systems, interfaces, and data flows rather than internal code structure. Reference detailed architecture documentation and interface catalogs internally.[^5][^2]

Table 6: Architecture components, interfaces, and trust boundaries

| Component | Interface Type | Trust Boundary | Notes |
|---|---|---|---|
| Mobile App (e.g., iOS/Android) | REST/GraphQL to backend | Untrusted client network | Public interface documented; no PHI in transport logs |
| Backend API Gateway | REST endpoints | Internal trusted zone | AuthN/AuthZ enforced; rate limiting; audit |
| Data Processing Service | Internal RPC | Segmented network | Input validation; integrity checks |
| Analytics/ML Service | Batch interface | Restricted segment | De-identified data; model validation artifacts |
| Identity Provider (IdP) | SAML/OIDC | External trust boundary | MFA/SSO; no secrets in README |

### API and Interface Documentation

Summarize publicly exposed interfaces and link to canonical API specifications (e.g., OpenAPI/Swagger) and SDK usage notes. Where possible, provide a sample request/response schema without PHI. Reference integration test evidence and error handling validation. For interoperability claims, summarize conformance testing and safeguards against communication failure.[^5]

### Installation, Configuration, and Deployment

Provide high-level steps for installing and configuring the software, linking to environment hardening guides and compliance configuration standards. Avoid secrets, provider-specific keys, or PHI. Emphasize adherence to encryption standards, audit controls, and session management. This section reassures readers that deployment practices respect security and privacy obligations.[^1]

### Testing, Validation, and Traceability

Summarize verification and validation activities across unit, integration, and system levels. Reference test plans, protocols, and reports. For analytical/statistical workflows used in clinical or performance contexts, document software versions and validation steps according to regulated software guidance.[^6] Maintain traceability from requirements to tests and results.

Table 7: Example traceability matrix structure

| Requirement | Design Artifact | Test Protocol | Test Result | Risk Control Link |
|---|---|---|---|---|
|REQ-001: Secure API access|SDS-001: API auth design|STP-001: Auth tests|TPR-001: Pass/Fail|RC-01: Access control policy|
|REQ-002: Data integrity|SDS-002: Integrity checks|STP-002: Checksum tests|TPR-002: Pass/Fail|RC-02: Integrity SOP|
|REQ-003: Transmission security|SDS-003: TLS config|STP-003: TLS tests|TPR-003: Pass/Fail|RC-03: Transmission security SOP|

### Performance and Clinical Metrics

SaMD performance should be presented across three pillars: clinical association, analytical validation, and clinical validation.[^5] For non-device health software handling ePHI, reliability, availability, latency, and security metrics are still critical.

Table 8: Clinical/analytical metrics, definitions, evidence pointers, and acceptance criteria

| Metric | Definition | Evidence Pointer | Acceptance Criteria (Context-Dependent) |
|---|---|---|---|
| Clinical association | Link between software output and clinical condition | Clinical evaluation report; literature benchmarks | Defined per intended use; align with risk file |
| Analytical validation | Accuracy and reliability of data processing | Benchmarks; synthetic datasets; validation protocols | Predefined thresholds tied to intended use |
| Clinical validation | Performance in target environment | System test report; clinical performance study | Evidence sufficient to support safety/effectiveness |
| Reliability/Availability | Uptime and fault tolerance | SLOs; operational test reports | Targets per service criticality and risk |
| Latency | Response time under normal/peak load | Performance test reports | Thresholds per clinical workflow needs |
| Security incidents | Reported vulnerabilities and resolution | Incident response logs; patch cadence | Time-to-mitigation aligned to risk and SLA |

For analytical/statistical tooling used in regulated contexts, document the software’s reliability and validation. The R Foundation’s guidance emphasizes that version/build identification and appropriate software testing procedures must be available; do not rely on undocumented or unvalidated tooling for pivotal analyses.[^6]

### Release, Versioning, SBOM, and Unresolved Anomalies

Provide version history, release notes, and a list of unresolved anomalies with risk assessments. Include pointers to SBOMs (including Software of Unknown Provenance, SOUP) and explain how release decisions and anomaly risk assessments are governed in the QMS. This practice demonstrates control over software change and transparency in residual risk.[^11]

### Support, Incident Response, and Vulnerability Disclosure

Document how users can obtain support, how safety issues are communicated, and how security vulnerabilities are reported and handled. Reference HIPAA-contingency planning and breach notification procedures for ePHI incidents, and describe coordination with regulators when required. This section operationalizes accountability and continuous safety monitoring.[^1]

### Licensing and Legal Notices

State the software license, third-party component licenses, and attributions. Include patent disclosures if applicable and any export control notices. Keep licensing summaries high-level and link to the full license text internally.

### How to Contribute (Optional)

Set governance expectations for contributions. Indicate code review requirements, testing gates, and change control linkage to QMS procedures. Public contributions should be treated with the same rigor as internal changes in regulated environments.[^3]

---

## Presenting Medical Compliance and Security Information

Compliance presentation must be truthful, non-misleading, and evidence-backed. Avoid marketing claims. Use precise language aligned to regulatory frameworks, and link to internal evidence artifacts rather than attempting to recreate comprehensive compliance documentation within the README. Align statements to HIPAA safeguards and FDA submission elements where relevant.[^1][^2]

Table 9: Recommended compliance language patterns for README statements

| Context | Recommended Language Pattern | Evidence Linkage |
|---|---|---|
| HIPAA applicability | “This software handles ePHI where applicable; safeguards are implemented per HIPAA Security Rule technical, administrative, and physical safeguards.” | Safeguard mapping; policies |
| BAA status | “Business Associate Agreements are executed where required to support permissible uses and disclosures of PHI.” | BAA repository |
| Access control | “Access is restricted to authorized users via unique identifiers and role-based policies; emergency access procedures are governed by SOPs.” | Access policy; emergency SOP |
| Audit controls | “System activity is logged and reviewed according to policy; audit trails are retained per regulatory requirements.” | Audit control plan |
| Transmission security | “ePHI in transit is protected using standard secure transport controls.” | TLS policy |

Table 10: HIPAA Safeguards → README statements → Evidence pointers

| Safeguard | README Statement | Evidence Pointer |
|---|---|---|
| Access Control | “Role-based access with unique user IDs and emergency access procedures.” | IAM policy; emergency SOP |
| Automatic Logoff | “Sessions terminate after inactivity per configuration standards.” | Session management policy |
| Encryption | “Data at rest and in transit is encrypted per policy.” | Crypto policy |
| Audit Controls | “Logs record and examine system activity.” | Audit plan; review cadence |
| Integrity | “Data integrity mechanisms (e.g., checksums, signatures) are implemented.” | Integrity SOP |
| Authentication | “Identity is verified prior to access; MFA/SSO may be required.” | Authentication policy |
| Transmission Security | “End-to-end protections guard ePHI during transmission.” | Secure transport SOP |

![HIPAA Security Rule—technical safeguards overview (HHS)](.pdf_temp/viewrange_chunk_2_6_10_1762307726/images/0ehlit.jpg)

The image reinforces the five technical safeguard standards. These concise patterns help teams avoid both under-sharing (which appears evasive) and over-sharing (which creates risk). They signal due diligence while pointing auditors to the right internal artifacts.[^1]

---

## Visual Diagram Best Practices for Healthcare Applications

Diagrams are often the first thing reviewers look for, and they must be carefully composed to convey architecture and data flows without revealing PHI or sensitive network details.

A high-level systems diagram should depict all relevant software systems, their communication pathways, the runtimes where code executes (e.g., Android, iOS, JVM), hosting environments, and network isolation configurations. Automation is discouraged for high-level views; manual diagrams preserve conceptual clarity and focus on what matters to compliance and safety.[^5] For data flow diagrams, label data categories, trust boundaries, and encryption zones. For network and security architecture, depict segmentation, isolation, and DMZ contexts without exposing specific IP addresses or detailed topology that should remain internal.

Table 11: Diagram type, purpose, required elements, compliance notes, and examples

| Diagram Type | Purpose | Required Elements | Compliance Notes | Example |
|---|---|---|---|---|
| High-level Systems | Show systems and communication pathways | Systems, interfaces, runtimes, hosting, network isolation | Avoid PHI; emphasize trust boundaries and interfaces | SaMD app + verification server + app server + CDN |
| Data Flow | Illustrate data categories and movement | Data categories, boundaries, encryption zones | Use de-identified examples; no PHI | Batch analytics pipeline with de-identified data |
| Network/Security Architecture | Show segmentation and isolation | Segments, DMZ, external integrations | Avoid detailed internal IPs; highlight controls | Segmented services with API gateway and IdP |

![HIPAA safeguard context to inform diagram labels (HHS)](.pdf_temp/viewrange_chunk_1_1_5_1762307729/images/1unc7w.jpg)

Label diagrams with safeguard-aware categories (e.g., “ePHI in transit,” “de-identified data,” “public interface”) to help auditors quickly see compliance intent without exposing sensitive specifics.[^1]

---

## Performance Metrics Presentation for Medical Software

Presenting performance metrics in a healthcare README requires careful categorization, clarity of definitions, and alignment with evidence. Use defined metric families—clinical, analytical, reliability/availability, latency, security, and operational—and provide context on how targets were set and validated.

Table 12: Metric category, definition, target, evidence pointer, acceptance criteria

| Category | Metric Definition | Target | Evidence Pointer | Acceptance Criteria |
|---|---|---|---|---|
| Clinical association | Relationship between output and clinical condition | Context-specific per intended use | Clinical evaluation | Aligned to risk management and labeling |
| Analytical validation | Correctness/consistency of processing | Defined thresholds per pipeline | Validation protocols/reports | Benchmarks or simulations; documented rationale |
| Clinical validation | Performance in target environment | Defined performance goals | System tests/clinical performance | Evidence sufficient to support safety/effectiveness |
| Reliability/Availability | Service uptime and fault tolerance | SLOs by service | Operational test reports | Targets per criticality and risk |
| Latency | Response time under load | Thresholds per workflow | Performance tests | Derived from clinical workflow requirements |
| Security incidents | Vulnerability disclosure and remediation | Time-to-mitigation targets | IR logs; patch cadence | Align to policy and SLA; coordinate with regulators if needed |

For analytical/statistical workflows, explicitly document software versions and validation steps. In regulated settings, sponsors are encouraged to consult review teams early regarding software suitability and testing procedures. Version/build identification and appropriate validation documentation are critical to maintaining scientific integrity.[^6][^5]

---

## Professional Presentation Standards for Healthcare Tech Projects

Professional presentation supports auditability and trust. Adopt a clinical tone, avoiding marketing language. Maintain version history and change logs for documentation itself, reflecting GDocPs and QMS expectations. Ensure documents are accessible and readable, with consistent terminology and clear structure.[^3]

Table 13: Documentation artifact, owner, approval steps, retention period, evidence location

| Artifact | Owner | Approval Steps | Retention | Evidence Location |
|---|---|---|---|---|
| README.md | Tech Writing Lead | Review by Engineering, Security, Regulatory | Life of product + archival | QMS repository |
| Architecture Diagram | Engineering Lead | Review by Security, Regulatory | Life of product + archival | QMS repository |
| API Specification | Engineering Lead | Review by Security, Product | Life of product + archival | API repo / QMS |
| Test Plans/Reports | QA Lead | Review by Engineering, Regulatory | As per QMS retention | Test management system |
| Risk Management File | Regulatory Lead | Review by Safety Committee | As per QMS retention | QMS repository |
| SBOM/Release Notes | Release Manager | Review by Engineering, Security | As per QMS retention | Release repository |

---

## Linking README Content to Full Evidence

Do not duplicate full documents in the public README. Instead, provide concise summaries and link to canonical evidence stored in internal repositories (QMS, design history file, risk management file, test repositories). Use consistent internal anchors so that auditors can quickly locate documents. This approach satisfies transparency without creating security risks or maintenance burdens.

Table 14: README section → Internal artifact → Repository → Access model → Notes

| README Section | Internal Artifact | Repository | Access Model | Notes |
|---|---|---|---|---|
| Overview & Intended Use | Intended use statement; labeling | QMS | Restricted | Align to premarket submission |
| Compliance & Security | Policies; safeguard mapping | QMS | Restricted | No PHI in public docs |
| Architecture | High-level diagrams; interface catalog | QMS | Restricted | Sensitive topology internal |
| API & Interfaces | OpenAPI specs; SDK docs | API repo | Public summary / Private detailed | Avoid PHI in examples |
| Testing & Validation | Test plans; protocols; reports | Test system | Restricted | Maintain traceability |
| Performance & Clinical Metrics | Evaluation reports; performance tests | QMS | Restricted | Align to intended use |
| Release & SBOM | Release notes; SBOM | Release repo | Public summary / Private SBOM | Include anomaly risk assessments |
| Support & Incident Response | IR SOP; contingency plan | QMS | Restricted | Coordinate with regulators as needed |

---

## Implementation Checklist and QA

Teams should validate the README against a structured checklist to ensure compliance, security, and readability before each release.

Table 15: Comprehensive README checklist

| Item | Verification Step | Status | Notes |
|---|---|---|---|
| Intended use clarity | Statements align with labeling and premarket submissions |  |  |
| HIPAA mapping | Safeguard matrix complete; evidence pointers valid |  |  |
| BAA status | BAAs listed or rationale for non-applicability |  |  |
| Architecture diagrams | High-level view present; no PHI or secrets |  |  |
| Interface documentation | Public endpoints summarized; detailed specs linked |  |  |
| Deployment guidance | Environment hardening referenced; no secrets |  |  |
| Test summaries | V&V overview present; traceability referenced |  |  |
| Metrics | Clinical/analytical/reliability/security metrics included |  |  |
| Versioning & SBOM | Version history, anomalies, SBOM pointers present |  |  |
| Incident response | Vulnerability disclosure and safety communications linked |  |  |
| Licensing | Licenses and attributions summarized |  |  |
| Contribution governance | Contribution rules aligned to QMS |  |  |

---

## Appendix: Template Examples and Source Mapping

Table 16: Template snippet, purpose, regulatory anchor, example artifact, notes

| Template Snippet | Purpose | Regulatory Anchor | Example Artifact | Notes |
|---|---|---|---|---|
| Compliance matrix | Summarize HIPAA safeguards | HIPAA Security Rule | Safeguard mapping table | Link to internal policies |
| Architecture overview | Show systems and interfaces | FDA guidance; IEC 62304 concepts | High-level systems diagram | No PHI; manual diagram preferred |
| Traceability summary | Link requirements to tests | FDA software V&V | Traceability matrix | Maintain in QMS |
| Performance metrics table | Present clinical/analytical metrics | FDA validation pillars | Metrics table | Context-dependent acceptance criteria |

For organization and to accelerate adoption, teams may leverage open regulatory templates as a starting point, then tailor content to their product and QMS. This promotes consistency while ensuring alignment with specific regulatory contexts.[^12]

---

## References

[^1]: Summary of the HIPAA Security Rule | HHS.gov. https://www.hhs.gov/hipaa/for-professionals/security/laws-regulations/index.html  
[^2]: Content of Premarket Submissions for Device Software Functions | FDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-premarket-submissions-device-software-functions  
[^3]: Good Documentation Practices for Medical Devices | MadCap Software. https://www.madcapsoftware.com/blog/good-documentation-practices-for-medical-devices/  
[^4]: Technical Safeguards—HIPAA Security Series #4 | HHS (PDF). https://www.hhs.gov/sites/default/files/ocr/privacy/hipaa/administrative/securityrule/techsafeguards.pdf  
[^5]: Medical Device Software Architecture Documentation (IEC 62304) | OpenRegulatory. https://openregulatory.com/articles/medical-device-software-architecture-documentation-iec-62304  
[^6]: R: Regulatory Compliance and Validation Issues—Guidance for the Use of R in Regulated Clinical Trial Environments | R Foundation (PDF). https://www.r-project.org/doc/R-FDA.pdf  
[^7]: HIPAA Compliance for Medical Software Applications | HIPAA Journal. https://www.hipaajournal.com/hipaa-compliance-for-medical-software-applications/  
[^8]: New FDA Guidance on Software Documentation for Medical Devices | Exponent. https://www.exponent.com/article/new-fda-guidance-software-documentation-medical-devices  
[^9]: Medical Device Software Guidance Navigator | FDA. https://www.fda.gov/medical-devices/regulatory-accelerator/medical-device-software-guidance-navigator  
[^10]: Federal Register Notice: Content of Premarket Submissions for Device Software Functions. https://www.federalregister.gov/d/2023-12723  
[^11]: Documentation for Medical Device Software | Sunstone Pilot. https://sunstonepilot.com/2021/08/documentation-for-medical-device-software/  
[^12]: OpenRegulatory Templates (ISO 13485, IEC 62304, ISO 14971, IEC 62366). https://github.com/openregulatory/templates

---

## Acknowledgment of Information Gaps

- No universal, single regulation defines a complete README schema. This report aligns to HIPAA Security Rule, FDA device software guidance, and GDocPs to propose a practical structure.[^1][^2][^3]
- Quantitative performance thresholds (e.g., acceptable latency or uptime targets) are context-dependent and should be derived from device class, intended use, and risk management evidence rather than prescribed here.
- International frameworks (e.g., EU MDR/IVDR and GDPR) are referenced indirectly via template availability and general practices; teams should consult domain-specific sources for jurisdiction-specific requirements.
- Diagram assets are concept examples; teams should create tailored visuals aligned to their systems and controls.